Migraderm Licensing and Service, LLC (Migraderm) is the exclusive agent representing Afgin Pharma, holder of US Patent No 8,329734 B2, which covers topical use of sumatriptan and other serotonin agonists for the treatment of migraine headaches.
Our objective is to license a nationwide network of high quality compounding pharmacies to bring this therapy to market across the United States, and to provide ongoing support to ensure our licensees' success.
For more information on Migraderm and how to become a licensee, please submit an information request or contact us at email@example.com.
AfGin Pharma, LLC was founded by Dr. Ronald Aung-Din, M.D. and holds both US and European patents for the Topical Regional Neuro-Affective migraine therapy.
Dr. Aung-Din has practiced General Neurology and Neuro-Psychiatry in Sarasota, Florida for over 25 years. He is board-certified by the American Board of Psychiatry and Neurology and a member of the American Academy of Neurology.
Migraderm Licensing & Service, LLC is seeking industry leading compounding pharmacies to participate in our licensee program. To learn more about Migraderm and how to become a licensee, please submit an information request by clicking the below link and a member of our Licensee Relations team will follow up with you.Request Information
The safety and effectiveness of this compound has not been demonstrated in a recognized clinical trial. Compounded drugs are not FDA-approved. The FDA does not verify the quality, safety and effectiveness of compounded drugs. Compounded drugs lack an FDA finding of manufacturing quality.
Migraderm Licensing and Service, LLC 90 Park Avenue, 17th Floor, New York, NY, 10016
© Copyright - 2013 Migraderm Licensing and Service, LLC